Ascendis Pharma A/S
$
112.76
-2.75 (-2.38%)
| Volume: | 381,515 | Avg Vol (1m): | 324,769 |
| Market Cap $: | 5.29 Bil | Enterprise Value $: | 4.50 Bil |
| P/E (TTM): | 0.00 | P/B: | 6.14 |
| Earnings Power Value | -706.89 |
| Net Current Asset Value | 17.47 |
| Tangible Book | 18.58 |
| Projected FCF | 0 |
| Median P/S Value | 79.77 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 8.2/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | No Debt |
Cash-To-Debt range over the past 10 years
Min: 68.56, Med: 10000, Max: 10000
Current: 10000
| |
| Equity-to-Asset | 0.94 |
Equity-to-Asset range over the past 10 years
Min: 0.16, Med: 0.9, Max: 0.95
Current: 0.94
| |
| Piotroski F-Score | 4 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 63.24 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | 8.49 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 0%
WACC 6.86%
| ||
Profitability & Growth : 2/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -1115.33 |
Operating Margin range over the past 10 years
Min: -7290.26, Med: -515.21, Max: 25.87
Current: -1115.33
| |
| Net Margin % | -900.61 |
Net Margin range over the past 10 years
Min: -8097.84, Med: -405.54, Max: 19.99
Current: -900.61
| |
| ROE % | -35.49 |
ROE range over the past 10 years
Min: -71.9, Med: -38.24, Max: 139.69
Current: -35.49
| |
| ROA % | -32.70 |
ROA range over the past 10 years
Min: -65.14, Med: -33.22, Max: 15.98
Current: -32.7
| |
| ROC (Joel Greenblatt) % | -1932.67 |
ROC (Joel Greenblatt) range over the past 10 years
Min: -5343.32, Med: -1499.83, Max: 303.45
Current: -1932.67
| |
| 3-Year Total Revenue Growth Rate | 10.80 |
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -58.6, Max: -7.6
Current: -7.6
| |
| 3-Year Total EBITDA Growth Rate | -60.00 |
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -33.3
Current: -33.3
| |
| 3-Year EPS w/o NRI Growth Rate | -33.50 |
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -33.5
Current: -33.5
|
» ASND's 30-Y Financials
Financials (Next Earnings Date: 2019-08-29)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:ASND
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325411   SIC : 2833 |
| Compare | NAS:HALO NAS:CBPO NAS:PBYI SZSE:300009 NAS:ANAB NAS:FOLD NYSE:EBS SHSE:600161 XBRU:ARGX NAS:ACAD SZSE:002821 XSWX:GALE XSWX:IDIA NAS:CRSP NAS:RARE NAS:IMMU SZSE:002603 NAS:CLVS SZSE:000990 HKSE:00570 |
| Traded in other countries | A71.Germany |
| Address | Tuborg Boulevard 5, Hellerup, DNK, DK-2900 |
| Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP etc. It operates mainly in USA, Germany, and Switzerland and derives the majority of its revenue from the US. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 6.14 |
PB Ratio range over the past 10 years
Min: 2.43, Med: 5.53, Max: 10.24
Current: 6.14
| |
| PS Ratio | 264.09 |
PS Ratio range over the past 10 years
Min: 15.85, Med: 186.82, Max: 5905
Current: 264.09
| |
| EV-to-EBIT | -27.71 |
EV-to-EBIT range over the past 10 years
Min: -29.86, Med: -9.85, Max: -3.6
Current: -27.71
| |
| EV-to-EBITDA | -28.10 |
EV-to-EBITDA range over the past 10 years
Min: -31.2, Med: -10, Max: -3.6
Current: -28.1
| |
| EV-to-Revenue | 249.54 |
EV-to-Revenue range over the past 10 years
Min: 15.4, Med: 182.1, Max: 6352.5
Current: 249.54
| |
| Current Ratio | 22.32 |
Current Ratio range over the past 10 years
Min: 0.77, Med: 9.87, Max: 22.32
Current: 22.32
| |
| Quick Ratio | 22.32 |
Quick Ratio range over the past 10 years
Min: 0.77, Med: 9.87, Max: 22.32
Current: 22.32
| |
| Days Sales Outstanding | 0.09 |
Days Sales Outstanding range over the past 10 years
Min: 0.09, Med: 33.73, Max: 133.93
Current: 0.09
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -17.80 |
3-Year Share Buyback Rate range over the past 10 years
Min: -44.2, Med: -29.7, Max: 0
Current: -17.8
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 6.07 |
Price-to-Tangible-Book range over the past 10 years
Min: 2.62, Med: 5.62, Max: 8.49
Current: 6.07
| |
| Price-to-Median-PS-Value | 1.41 |
Price-to-Median-PS-Value range over the past 10 years
Min: 0.09, Med: 0.99, Max: 31.63
Current: 1.41
| |
| Earnings Yield (Joel Greenblatt) % | -3.57 |
Earnings Yield (Greenblatt) range over the past 10 years
Min: -27.8, Med: -10.15, Max: -3.34
Current: -3.57
|
More Statistics
| Revenue (TTM) (Mil) $ | 18.12 |
| EPS (TTM) $ | -3.85 |
| Beta | 0.79 |
| Volatility % | 65.98 |
| 52-Week Range $ | 53.21 - 133.96 |
| Shares Outstanding (Mil) | 46.93 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 4 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | Y |
| CFROA > ROA | N |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | Y |